Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2013

View Archived Issues

New copper-based diagnostic imaging agents for Alzheimer's disease synthesized

Trovagene enters into pharmaceutical collaboration for oncogene mutation detection study

New collaboration to identify biomarkers of Limb-girdle muscular dystrophy 2B

Pharmacokinetics of propofol prodrugs HX-0969w and fospropofol compared

Inhibition of CDK9 explored for CLL at the University of South Australia

Chinese researchers report synthesis of novel DPP IV inhibitors for type 2 diabetes

Multikinase inhibitor DCB-R0237 shows promise in vivo

Novel LSD1 inhibitors display good pharmacological properties

Discovery Labs submits IND for Aerosurf

NNZ-2566 obtains FDA fast track status for fragile X syndrome

Once-daily Striverdi Respimat approved in first E.U. countries

AbbVie details activity of antibody-drug conjugate ABT-414

Health Canada approves Stivarga for gastrointestinal stromal tumors

MGN-1404 trial starts in malignant melanoma

Bayer Intellectual Property patents new NCX1 inhibitors

Piramal Enterprises synthesizes new anticancer agents

Germany's G-BA confirms benefits of Jetrea in vitreomacular traction

Polish researchers design novel CYP1B1 inhibitors for cancer

German researchers disclose novel mGlu5 receptor antagonists

FDA approves Opsumit for PAH

Array BioPharma and Genentech patent new BACE1 inhibitors

FDA approves Cimzia for ankylosing spondylitis, issues complete response letter for axSpA

Meda completes acquisition of Acton Pharmaceuticals

FDA awards orphan drug marketing exclusivity to Ixiaro for pediatric indication

Gene therapy product for spinal muscular atrophy gets fast track designation from FDA

Ariad discontinues EPIC trial of Iclusig in newly diagnosed CML

FDA issues complete response letter for Iluvien

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.